Media stories about Cronos Group (NASDAQ:CRON) have been trending somewhat positive recently, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of media coverage by analyzing more than 6,000 blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Cronos Group earned a news sentiment score of 0.86 on their scale. InfoTrie also assigned media stories about the company an news buzz score of 10 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company’s share price in the near future.

Here are some of the media stories that may have effected Cronos Group’s ranking:

Shares of NASDAQ:CRON opened at $15.40 on Monday. The firm has a market capitalization of $4.69 billion, a price-to-earnings ratio of -192.50 and a beta of 3.84. Cronos Group has a 1 year low of $5.61 and a 1 year high of $25.10.

Cronos Group (NASDAQ:CRON) last announced its quarterly earnings data on Thursday, May 9th. The company reported $0.36 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.02) by $0.38. The firm had revenue of $6.47 million during the quarter, compared to the consensus estimate of $6.87 million. Cronos Group had a return on equity of 181.38% and a net margin of 2,107.83%. The company’s revenue for the quarter was up 119.3% compared to the same quarter last year. On average, equities research analysts expect that Cronos Group will post -0.04 earnings per share for the current fiscal year.

A number of research firms recently commented on CRON. Zacks Investment Research raised Cronos Group from a “strong sell” rating to a “hold” rating in a research report on Friday. Pi Financial reissued a “neutral” rating and issued a $24.00 price target on shares of Cronos Group in a research report on Tuesday, March 26th. CIBC set a $30.00 price target on Cronos Group and gave the company a “buy” rating in a research report on Wednesday, March 27th. Canaccord Genuity lowered Cronos Group from a “hold” rating to a “sell” rating and set a $17.00 price target for the company. in a research report on Wednesday, March 27th. Finally, Bank of America began coverage on Cronos Group in a research report on Wednesday, April 17th. They issued an “underperform” rating and a $13.00 price target for the company. Five equities research analysts have rated the stock with a sell rating, five have issued a hold rating and one has issued a buy rating to the stock. Cronos Group has a consensus rating of “Hold” and a consensus price target of $17.03.

TRADEMARK VIOLATION WARNING: This story was originally posted by Daily Political and is the sole property of of Daily Political. If you are reading this story on another website, it was illegally copied and reposted in violation of US and international copyright and trademark laws. The original version of this story can be read at

About Cronos Group

Cronos Group Inc, formerly known as PharmaCan Capital Corp., is a principal investment firm. The firm seeks to invest in companies either licensed, or actively seeking a license, to produce medical marijuana pursuant to Canada's Marihuana for Medical Purposes Regulations “MMPR”. The firm typically invests in companies based in Canada.

Featured Story: Day Trading

Receive News & Ratings for Cronos Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cronos Group and related companies with's FREE daily email newsletter.